Robin Farmanfarmaian is a Silicon Valley based professional speaker and entrepreneur working in cutting edge tech poised to impact 100M people or more. Robin has been involved with over 20 early-stage biotech and healthcare startups, including working with small molecules found using AI for drug discovery to cure cancer (p53 & AhR pathways).

She has also worked on medical devices including inhaled insulin and sleep apnea, and co-founded a non-profit that worked with DARPA, the DoD, and the White House to help fund scientists and create a scientific roadmap to solve cryopreservation and tissue engineering for organ transplants. She is an advisor to multiple companies, including: Luxsonic Technologies, working on a portable and modular radiology reading room in VR; Alacrity Care, remote patient monitoring and data analytics for oncology; and ConceptVines, a VC fund and product engineering firm focused on disruptive tech.

With over 180 speaking engagements in 15 countries, she educates audiences on many aspects of technology intersecting healthcare, including artificial intelligence, longevity, and the shift in healthcare delivery to the patient’s home.

She has written 4 books, including “The Patient as CEO: How Technology Empowers the Healthcare Consumer" (2015) and “How AI Can Democratize Healthcare: The Rise in Digital Care” (2022) written with Michael Ferro, an entrepreneur with many technology patents and multiple large exits, including the 2015 sale of Merge Healthcare to IBM for $1B.